SK722002A3 - Method for down-regulating GDF-8 activity - Google Patents

Method for down-regulating GDF-8 activity Download PDF

Info

Publication number
SK722002A3
SK722002A3 SK72-2002A SK722002A SK722002A3 SK 722002 A3 SK722002 A3 SK 722002A3 SK 722002 A SK722002 A SK 722002A SK 722002 A3 SK722002 A3 SK 722002A3
Authority
SK
Slovakia
Prior art keywords
gdf
nucleic acid
cell
leu
lys
Prior art date
Application number
SK72-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Torben Halkier
Soren Mouritsen
Steen Klysner
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Publication of SK722002A3 publication Critical patent/SK722002A3/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55516Proteins; Peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55522Cytokines; Lymphokines; Interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Control Of Eletrric Generators (AREA)
  • Debugging And Monitoring (AREA)
SK72-2002A 1999-07-20 2000-07-20 Method for down-regulating GDF-8 activity SK722002A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199901014 1999-07-20
US14527599P 1999-07-26 1999-07-26
PCT/DK2000/000413 WO2001005820A2 (fr) 1999-07-20 2000-07-20 Procede permettant de faire decroitre l'activite du gdf-8

Publications (1)

Publication Number Publication Date
SK722002A3 true SK722002A3 (en) 2003-02-04

Family

ID=26065065

Family Applications (1)

Application Number Title Priority Date Filing Date
SK72-2002A SK722002A3 (en) 1999-07-20 2000-07-20 Method for down-regulating GDF-8 activity

Country Status (21)

Country Link
US (2) US7056512B1 (fr)
EP (1) EP1200119A2 (fr)
JP (1) JP2003506325A (fr)
KR (1) KR100750695B1 (fr)
CN (1) CN1384757A (fr)
AU (1) AU778470B2 (fr)
CA (1) CA2379852A1 (fr)
EA (1) EA005248B1 (fr)
EE (1) EE200200025A (fr)
HK (1) HK1048937A1 (fr)
HR (1) HRP20010900A2 (fr)
HU (1) HUP0201861A3 (fr)
IL (1) IL146845A0 (fr)
MX (1) MXPA01013232A (fr)
NO (1) NO20016252L (fr)
NZ (1) NZ517058A (fr)
PL (1) PL353855A1 (fr)
SK (1) SK722002A3 (fr)
TR (2) TR200400621T2 (fr)
WO (1) WO2001005820A2 (fr)
ZA (1) ZA200109901B (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393682B1 (en) * 1993-03-19 2008-07-01 The Johns Hopkins University School Of Medicine Polynucleotides encoding promyostatin polypeptides
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
AU765214B2 (en) * 1998-05-06 2003-09-11 Metamorphix International, Inc. Methods for treating diabetes by inhibiting gdf-8
US7037501B2 (en) 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
TWI329129B (en) 2001-02-08 2010-08-21 Wyeth Corp Modified and stabilized gdf propeptides and uses thereof
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2004019975A2 (fr) * 2002-08-30 2004-03-11 Glaxo Group Limited Vaccin
US7261893B2 (en) 2002-10-22 2007-08-28 Wyeth Neutralizing antibodies against GDF-8 and uses therefor
AU2003301195B2 (en) * 2002-12-20 2010-01-07 Amgen Inc. Binding agents which inhibit myostatin
US7785587B2 (en) 2003-06-02 2010-08-31 Wyeth Therapeutic methods for muscular or neuromuscular disorders
ITMI20071072A1 (it) 2007-05-25 2008-11-26 Lps Electronics S R L Apparecchiatura per la rilevazione automatica dello stato di calore di una scrofa.
US7371726B2 (en) * 2003-12-31 2008-05-13 Schering-Plough Animal Health Corporation Neutralizing GDF8 epitope-based growth enhancing vaccine
JP4688483B2 (ja) 2004-04-15 2011-05-25 株式会社テクノネットワーク四国 フォリスタチン変異体ポリペプチド
WO2006036074A1 (fr) 2004-09-30 2006-04-06 Orico Limited Isoforme de myostatine
PL2407486T3 (pl) 2005-08-19 2018-05-30 Wyeth Llc Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
CA2693378C (fr) 2006-08-03 2020-04-14 Orico Limited Antagonistes vis-a-vis de la myostatine
CN100450545C (zh) * 2006-08-03 2009-01-14 中国医学科学院基础医学研究所 肌肉生长抑制素在制备抗肿瘤药物中的应用
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
PL2170396T3 (pl) 2007-08-03 2017-07-31 Summit (Oxford) Limited Kombinacje leków do leczenia dystrofii mięśniowej Duchenne'a
KR100857861B1 (ko) * 2007-10-15 2008-09-11 주식회사 바이오리더스 Myo-2 펩타이드 중합체와 마이오스타틴의 융합단백질표면발현용 벡터 및 상기 벡터로 형질전환된 미생물
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
WO2013003983A1 (fr) * 2011-07-06 2013-01-10 湖北省农业科学院畜牧兽医研究所 Locus de myostatine porcine et son utilisation
RS56796B1 (sr) 2011-11-14 2018-04-30 Regeneron Pharma Kompozicije i postupci za uvećanje mišićne mase i jačine mišića specifičnim antagonizovanjem gdf8 i/ili aktivina a
NZ702269A (en) 2012-06-15 2017-07-28 Pfizer Improved antagonist antibodies against gdf-8 and uses therefor
EP3711771A1 (fr) 2012-08-01 2020-09-23 Ikaika Therapeutics, LLC Atténuation de lésions tissulaires et de la fibrose par l'intermédiaire de la protéine de liaison bêta (ltbp4) d'un facteur de croissance de transformation latente
JP2016521283A (ja) 2013-05-06 2016-07-21 スカラー ロック インコーポレイテッドScholar Rock,Inc. 成長因子モジュレーションのための組成物および方法
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素a之抗體及其用途
EP2960653A1 (fr) * 2014-06-24 2015-12-30 Stichting Kwaliteitsgarantie Vleeskalversector Trousse de diagnostic et procédé pour l'identification de la manipulation de la masse musculaire chez un animal domestique
CN107771081A (zh) 2015-04-15 2018-03-06 瑞泽恩制药公司 用gdf8抑制剂增加力量和功能的方法
CA3092334A1 (fr) 2018-03-01 2019-09-06 Regeneron Pharmaceuticals, Inc. Procedes de modification de composition corporelle
AU2019406214A1 (en) 2018-12-21 2021-08-05 Northwestern University Use of annexins in preventing and treating muscle membrane injury
US20220062299A1 (en) 2018-12-26 2022-03-03 Northwestern University Use of glucocorticoid steroids in preventing and treating conditions of muscle wasting, aging and metabolic disorder

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6607884B1 (en) 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
ATE415173T1 (de) 1993-09-14 2008-12-15 Pharmexa Inc Pan dr-bindeproteinen zur erhöhung der immunantwort
AUPO390396A0 (en) 1996-11-29 1996-12-19 Csl Limited Novel promiscuous T helper cell epitopes
CN1178955C (zh) 1997-04-15 2004-12-08 法默卡有限公司 经修饰的TNFα分子和编码该TNFα分子的DNA以及含有该TNFα分子和该DNA的疫苗
JP4368522B2 (ja) 1997-07-14 2009-11-18 ユニバーシティー オブ リージ 哺乳動物におけるダブルマスル化を引き起こすミオスタチン遺伝子の変異
JP2003528024A (ja) * 1997-12-16 2003-09-24 バレンティス・インコーポレーテッド 製剤化された核酸分子の無針注入
GB2333706A (en) 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers

Also Published As

Publication number Publication date
NZ517058A (en) 2004-04-30
KR20020026544A (ko) 2002-04-10
ZA200109901B (en) 2003-05-28
MXPA01013232A (es) 2005-05-24
JP2003506325A (ja) 2003-02-18
TR200400621T2 (tr) 2004-08-23
CN1384757A (zh) 2002-12-11
NO20016252L (no) 2002-03-15
HK1048937A1 (zh) 2003-04-25
EP1200119A2 (fr) 2002-05-02
US7070784B1 (en) 2006-07-04
AU5967500A (en) 2001-02-05
HUP0201861A3 (en) 2004-07-28
IL146845A0 (en) 2002-07-25
WO2001005820A2 (fr) 2001-01-25
HUP0201861A2 (en) 2002-09-28
US7056512B1 (en) 2006-06-06
WO2001005820A3 (fr) 2001-07-19
CA2379852A1 (fr) 2001-01-25
EE200200025A (et) 2003-04-15
AU778470B2 (en) 2004-12-09
HRP20010900A2 (en) 2003-08-31
EA200200182A1 (ru) 2002-06-27
TR200200133T2 (tr) 2002-05-21
EA005248B1 (ru) 2004-12-30
NO20016252D0 (no) 2001-12-19
KR100750695B1 (ko) 2007-08-22
PL353855A1 (en) 2003-12-01

Similar Documents

Publication Publication Date Title
SK722002A3 (en) Method for down-regulating GDF-8 activity
DE69924392T2 (de) Verfahren zur hemmung der aktivität von osteoprotegerin-liganden
US8652488B2 (en) Insulin B chain autoantigen composition
ES2318654T3 (es) Composiciones inmunologicas para modular la miostatina en vertebrados.
AU2006312847A1 (en) Therapeutic vaccines targeting HMGB1
CZ20013709A3 (cs) Analog interleukinu 5, fragment nukleové kyseliny, vektor, buňka, přípravky a pouľití
US20020172673A1 (en) Method for down-regulating IgE
US20080253993A1 (en) Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope
AU2002233166B2 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
EP1539232A1 (fr) Immunisation contre la ghreline autologue
AU2002233166A1 (en) Synthetic vaccines comprising polyhydroxypolymer carriers
AU2004235875A1 (en) Immunogenic human TNF alpha analogues with reduced cytotoxicity and methods of their preparation
KR20050052499A (ko) 자가 그렐린에 대한 면역화
BOEVING et al. Patent 2498739 Summary
EP1541587A2 (fr) Méthode pour diminuer l'activité du ligand de l'ostéoprotégérine

Legal Events

Date Code Title Description
FB9A Suspension of patent application procedure